Marty Makary Was Too Independent for This Administration. That Should Worry Everyone.

Marty Makary spent more than a decade writing and lecturing about how the FDA moved too slowly — how excess caution cost lives, how bureaucratic inertia protected the status quo at the expense of innovation. He was Trump’s pick to fix it. He was confirmed by a Republican Senate in March 2025, sworn in, and set to work.

Thirteen months later, the White House pushed him out. Not because he defended the status quo. Because he was insufficiently compliant on two specific political priorities — and two different political pressure campaigns treated that resistance as defiance.

This is what the Makary resignation actually reveals. It’s not a story about regulatory philosophy, or whether the FDA approves drugs fast enough, or even about vaping or abortion pills. It’s a story about what happens when regulatory independence stops being a structural feature of an agency and becomes a privilege that can be revoked by whoever has the right phone number at the White House.

When that happens, the FDA’s approval authority stops meaning anything independent. It becomes a ratification stamp that political access can override. Every American who takes a prescription drug, uses a medical device, or trusts that their food has been reviewed for safety has a stake in whether that remains true.

What the Vaping Fight Revealed

The immediate trigger for Makary’s departure was a specific product authorization: the FDA’s approval of fruit-flavored e-cigarettes from the company Glas Inc. on May 6.

The FDA had long resisted authorizing broadly appealing flavored vaping products, citing evidence that such products disproportionately attract teenagers. This is not an obscure argument — it was the scientific basis for years of agency policy. Reporting from CBS News found that Makary opposed the May 6 approval. The Wall Street Journal reported that President Trump personally pressed Makary to authorize it. When the approval went through over the commissioner’s objections, the sequence that ended his tenure had already started. Health and Human Services Secretary Robert F. Kennedy Jr. made the final call to replace him. Kyle Diamantas, a lawyer serving as the FDA’s deputy commissioner for food, was named acting commissioner immediately.

The practical implication of what happened here isn’t abstract: a sitting president intervened to reverse the scientific judgment of his own FDA commissioner on a specific product authorization. The commissioner’s professional assessment — that the evidence didn’t support approval — was overruled by executive pressure.

You may have a different view of where flavored vaping products should land on the regulatory spectrum. That’s a legitimate policy debate worth having. But the procedure that resolved it wasn’t a debate. It was a hierarchy: whoever has the president’s attention wins.

There’s a downstream effect the pharmaceutical industry noticed, and it wasn’t the deregulatory relief many had expected. Specialty drugmakers developing therapies for rare and hard-to-treat diseases reported receiving new rejection letters and demands for additional clinical studies on applications that had previously received the green light from FDA scientific staff. The agency’s posture under Makary wasn’t consistently permissive or consistently strict. It was unpredictable. For an industry that plans clinical development across five- and ten-year investment horizons, unpredictability is its own category of regulatory failure — separate from, and in some ways worse than, being slow.

The Mifepristone Case Makes the Same Point From the Other Direction

The second line of pressure on Makary came from a different political coalition, which is precisely why it matters.

Mifepristone has been FDA-approved since 2000. Its safety profile over 25 years of approved use is among the most extensively documented in modern pharmacy. In September 2025, HHS Secretary Kennedy requested a formal safety review, and Makary launched one. FDA career staff estimated that a comprehensive review of a widely used, heavily studied drug would take through late 2026. That timeline became a political problem.

Susan B. Anthony Pro-Life America — among the most influential anti-abortion organizations in Washington — publicly called for Makary’s removal, citing the review’s pace as evidence he wasn’t serious about the administration’s priorities. Administration officials reportedly told the New York Times that the extended timeline, which stretched past the midterm elections, was treated internally as a deliberate act of delay.

The Supreme Court is already weighing emergency appeals over a federal court ruling that would ban mail-order dispensing of mifepristone across all 50 states. What Diamantas does with the incomplete safety review is now a live question, and the groups that pushed for Makary’s removal have already signaled their expectations.

The structure of the complaint about the mifepristone review is worth examining carefully: a regulatory timeline, grounded in the FDA’s internal scientific process, was treated as political bad faith because it didn’t produce a desired outcome before a politically significant deadline. That’s not a demand for regulatory reform. It’s a demand that science produce a predetermined outcome on a political schedule.

The vaping case and the mifepristone case are mirror images, not opposites. The political valences differ — industry pressure on one side, advocacy group pressure on the other. The structural mechanism is identical: political actors with executive-branch access dictating the outcome of specific FDA determinations.

The Deeper Damage: Expertise That Can’t Be Quickly Replaced

Makary’s departure matters. The institutional damage that preceded it matters more.

Dr. Richard Pazdur — director of the FDA’s Oncology Center of Excellence, with oversight of hundreds of cancer drug approvals over more than two decades — announced his retirement just three weeks after Makary was sworn in in March 2025. Pazdur didn’t leave because of a fight over a specific product. He left because he assessed where the agency was heading and concluded it was incompatible with the rigorous evaluation process he had spent his career building. After his departure, reporting from BioSpace found that only three veterans remained in the FDA’s senior scientific ranks.

This matters in a concrete, practical way. Drug approval isn’t primarily a bureaucratic process. It’s a technical judgment that requires deep institutional knowledge: clinical trial design, safety signal detection, the post-market surveillance patterns of drug classes, decades of precedent on how similar molecules behaved. That expertise accumulates over careers. It doesn’t regenerate in a staffing cycle.

The FDA’s recent move to open early access to a promising treatment for pancreatic cancer that nearly doubled survival time in trials happened despite the institutional turbulence — because scientific staff can produce serious work through political noise, at least for a while. But the pace and consistency of that work depends on stable expert leadership. An acting commissioner with a food safety and legal background can keep the lights on. He cannot replace what left when Pazdur and dozens of other career specialists departed.

The Counterargument, and Why It Doesn’t Resolve This

The strongest response to everything above is the argument Makary himself spent years making: the FDA moves too slowly, excess caution kills people, innovation should be faster. That argument is not wrong. The FDA has genuine process problems that harm patients who could benefit from therapies that take years longer than necessary to reach them.

But there are two very different kinds of regulatory reform, and conflating them is how this situation gets misread.

The first kind says: change the evaluation framework so that good evidence produces faster decisions, regardless of who made the drug or who’s asking for approval. Reform trial design requirements. Improve the Breakthrough Therapy pathway. Reduce procedural redundancy where it creates delay without adding rigor.

The second kind says: approve this specific product because this specific person wants it by this specific date.

What happened in the Glas flavored-vape authorization — a president overriding his own commissioner’s judgment on a particular product — is categorically the second kind. So is treating a safety review timeline as political bad faith because it inconveniently extends past an election. These are not process improvements. They are political overrides of individual scientific determinations.

And the moment that principle is established — that political access can change individual FDA outcomes — the agency loses the one thing that makes its authority worth anything: the predictability that its decisions reflect evidence.

What Every Patient Loses When This Principle Holds

The FDA regulates products that account for roughly one-quarter of every consumer dollar spent in the United States. Prescription drugs. Medical devices. Food safety. Vaccines. Dietary supplements. The scope of what the agency does, and whom it affects, makes it one of the most consequential regulatory institutions in the world.

That authority functions because FDA approval means something — because patients, doctors, and hospital systems have broadly trusted that an approved drug met a real evidentiary threshold rather than a negotiable one. Drug companies invest billions in clinical development because the pathway, however frustrating, is known and consistent.

When any political coalition can call enough contacts to change a specific FDA outcome — whether over vaping, abortion pills, or whatever product next becomes sufficiently important to someone with White House access — the threshold loses its meaning. Not all at once, but consistently, in ways that are measurable only in retrospect.

The FDA’s landmark recent approvals — including this year’s authorization of the first gene therapy for genetic deafness — demonstrate that the agency’s scientific staff remain capable of landmark work even through turbulence. The question isn’t whether the FDA can still produce important decisions. It’s whether those decisions will continue to mean what they’re supposed to mean when a commissioner can be replaced for not producing the right one fast enough.

Makary’s tenure ended because he was, in two specific cases, too independent for the people above him. The answer to that problem is not a more compliant replacement. It’s a serious reckoning with what it costs everyone when compliance becomes the job requirement.